Gene mutation affects breast cancer survival chance

June 18, 2014
Mammograms showing a normal breast (left) and a cancerous breast (right). Credit: Wikipedia.

Women with a specific gene mutation have a higher risk of dying from a type of breast cancer, said a study Tuesday that raised prospects of targeted drugs.

Previous research had shown that the chances of surviving breast after treatment were partly inherited. It was suspected that genes in the body's immune system were involved, but it was unclear which ones.

Now scientists link a variant in CCL20—a gene involved in immune response—to a higher risk of death for who have undergone chemotherapy for so-called oestrogen receptor negative (ER-) cancer.

The discovery "can represent ideal targets for tailored therapeutics, and may also enhance our current prognostic prediction capabilities," said the results published in the journal Nature Communications.

The team used data from numerous studies involving more than 2,600 women in different countries.

They looked at protein-coding changes in genes among women who had received chemotherapy for ER- cancer, a category that affects a minority of patients and is harder to treat than ER+ cancer.

The team adjusted the results for possibly confounding traits like a patient's age at diagnosis and tumour size.

The discovery explained only a small fraction of the variation associated with breast cancer survival, and more mutations must be uncovered to fully understand the genetic basis of ER- prognosis, wrote the researchers.

In a separate breast cancer study published online by the British Medical Journal (BMJ), researchers from Norway and the United States found that mammograms carried out once every two years may reduce death risk by about 28 percent.

About 27 deaths from can be avoided for every 10,000 women who did mammography screening—or about one in 368, said the team after analysing data from all women in Norway aged 50 to 79 between 1986 and 2009.

"Breast cancer deaths occurred in 1,175 of the women invited to mammography screening and in 8,996 of the women who were not," the team wrote, calling the link "substantial".

The finding adds to the ongoing debate about the value of such scans versus the dangers of overdiagnosis, which sees some women undergo invasive treatment for cancers that would never have made them ill or even been found without a mammogram.

In a comment also carried by bmj.com, two American professors of medicine, Joann Elmore and Russell Harris, said the team had by no means put the issue to bed.

"The Norwegian study largely confirms what is already known: the benefits of screening mammography are modest at best," the pair wrote.

"While the benefits are small, the harms of screening are real and include overdiagnosis, psychological stress, and exorbitant healthcare costs."

Explore further: New study suggests benefit of screening on breast cancer deaths

Related Stories

New study suggests benefit of screening on breast cancer deaths

June 17, 2014
Invitation to modern mammography screening may reduce deaths from breast cancer by about 28 percent, suggests a study from Norway published in BMJ. This means that for every 10,000 women invited to screening, about 27 deaths ...

MRIs plus mammograms best for high-risk women, study finds

June 17, 2014
(HealthDay)—For the best chance at spotting breast cancer early, women at high risk need frequent MRI screenings along with mammograms, a large Canadian study contends.

Nonscreened patients with breast cancer need more treatment than screened patients

May 7, 2014
Screening 40- to 49-year-old women for breast cancer has additional benefits beyond the proven decrease in mortality rate. Patients screened with mammography are statistically less likely to undergo chemotherapy, avoiding ...

Report: Breast cancer incidence rates converging among white and African-American women

October 1, 2013
Breast cancer incidence rates increased slightly among African American women from 2006 to 2010, bringing those rates closer to the historically higher rates among white women, according to a new analysis by American Cancer ...

Immune cells found near tumours boost breast cancer survival

June 10, 2014
Women with breast cancer are 10 per cent more likely to survive for five years or more if they have certain immune cells near their tumour, according to research published in Annals of Oncology today.

Annual screening does not cut breast cancer deaths, Canadian study suggests

February 11, 2014
Annual screening in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care, concludes a 25-year study from Canada published in BMJ today.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.